Menarini Group and Radius Health, Inc. present a subgroup anal...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy and BOSTON, June 6, 2022 /PRNewswire-AsiaNet/-- Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- adva...
Authors: LATEST ASIANET NEWS RELEASES